Nonparametric Estimation in a Markov “Illness–Death” Process from Interval Censored Observations with Missing Intermediate Transition Status

In many clinical trials patients are intermittently assessed for the transition to an intermediate state, such as occurrence of a disease-related nonfatal event, and death. Estimation of the distribution of nonfatal event free survival time, that is, the time to the first occurrence of the nonfatal event or death, is the primary focus of the data analysis. The difficulty with this estimation is that the intermittent assessment of patients results in two forms of incompleteness: the times of occurrence of nonfatal events are interval censored and, when a nonfatal event does not occur by the time of the last assessment, a patient's nonfatal event status is not known from the time of the last assessment until the end of follow-up for death. We consider both forms of incompleteness within the framework of an "illness-death" model. We develop nonparametric maximum likelihood (ML) estimation in an "illness-death" model from interval-censored observations with missing status of intermediate transition. We show that the ML estimators are self-consistent and propose an algorithm for obtaining them. This work thus provides new methodology for the analysis of incomplete data that arise from clinical trials. We apply this methodology to the data from a recently reported cancer clinical trial (Bonner et al., 2006, New England Journal of Medicine354, 567-578) and compare our estimation results with those obtained using a Food and Drug Administration recommended convention.

[1]  Niels Keiding,et al.  Education and second birth rates in Denmark 1981-1994 , 2007 .

[2]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[3]  Jacques Bernier,et al.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.

[4]  S. Grundy,et al.  The changing face of cardiovascular risk. , 2005, Journal of the American College of Cardiology.

[5]  D Commenges,et al.  A Penalized Likelihood Approach for a Progressive Three‐State Model with Censored and Truncated Data: Application to AIDS , 1999, Biometrics.

[6]  Karl Bang Christensen,et al.  Analyzing sickness absence with statistical models for survival data. , 2007, Scandinavian journal of work, environment & health.

[7]  Niels Keiding,et al.  Event history analysis and the cross‐section , 2006, Statistics in medicine.

[8]  I M Longini,et al.  Nonparametric Maximum Likelihood Estimation for Competing Risks Survival Data Subject to Interval Censoring and Truncation , 2001, Biometrics.

[9]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[10]  B. Turnbull The Empirical Distribution Function with Arbitrarily Grouped, Censored, and Truncated Data , 1976 .

[11]  V. Noronha,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[12]  Jianguo Sun,et al.  Variance estimation of a survival function for interval‐censored survival data , 2001, Statistics in medicine.

[13]  Halina Frydman,et al.  Nonparametric estimation of a Markov ‘illness-death’ process from interval-censored observations, with application to diabetes survival data , 1995 .

[14]  Marek Pawlicki,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[15]  D Commenges,et al.  Inference for multi-state models from interval-censored data , 2002, Statistical methods in medical research.

[16]  Daniel Commenges,et al.  A penalized likelihood approach for an illness-death model with interval-censored data: application to age-specific incidence of dementia. , 2002, Biostatistics.

[17]  B. Efron The two sample problem with censored data , 1967 .

[18]  Halina Frydman,et al.  A Nonparametric Estimation Procedure for a Periodically Observed Three‐State Markov Process, with Application to Aids , 1992 .

[19]  Brian Peacock,et al.  Empirical Distribution Function , 2010 .

[20]  J Grüger,et al.  The validity of inferences based on incomplete observations in disease state models. , 1991, Biometrics.

[21]  Carmen Cadarso-Suárez,et al.  Multi-state models for the analysis of time-to-event data , 2009, Statistical methods in medical research.

[22]  Sally Hollis,et al.  A graphical sensitivity analysis for clinical trials with non‐ignorable missing binary outcome , 2002, Statistics in medicine.

[23]  Bradley Efron,et al.  Censored Data and the Bootstrap , 1981 .

[24]  Christopher M O'Connor,et al.  Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. , 2004, JAMA.